X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs IPCA LABS - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. IPCA LABS FRESENIUS KABI ONCO./
IPCA LABS
 
P/E (TTM) x 22.1 27.5 80.6% View Chart
P/BV x 3.1 2.1 147.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 FRESENIUS KABI ONCO.   IPCA LABS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
IPCA LABS
Mar-17
FRESENIUS KABI ONCO./
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs176643 27.4%   
Low Rs79503 15.6%   
Sales per share (Unadj.) Rs37.7254.4 14.8%  
Earnings per share (Unadj.) Rs5.116.1 31.7%  
Cash flow per share (Unadj.) Rs6.729.8 22.6%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs42.5194.6 21.9%  
Shares outstanding (eoy) m158.23126.20 125.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.3 149.9%   
Avg P/E ratio x25.035.7 70.1%  
P/CF ratio (eoy) x18.919.2 98.4%  
Price / Book Value ratio x3.02.9 101.6%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m20,13572,300 27.8%   
No. of employees `0001.213.3 8.7%   
Total wages/salary Rs m7036,960 10.1%   
Avg. sales/employee Rs Th5,176.22,413.5 214.5%   
Avg. wages/employee Rs Th610.4523.2 116.7%   
Avg. net profit/employee Rs Th699.6152.4 458.9%   
INCOME DATA
Net Sales Rs m5,96332,106 18.6%  
Other income Rs m18226 8.0%   
Total revenues Rs m5,98132,332 18.5%   
Gross profit Rs m1,4304,448 32.2%  
Depreciation Rs m2581,730 14.9%   
Interest Rs m-26241 -10.8%   
Profit before tax Rs m1,2162,703 45.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342675 50.7%   
Profit after tax Rs m8062,028 39.7%  
Gross profit margin %24.013.9 173.1%  
Effective tax rate %28.125.0 112.6%   
Net profit margin %13.56.3 214.0%  
BALANCE SHEET DATA
Current assets Rs m5,10217,340 29.4%   
Current liabilities Rs m2,3859,559 25.0%   
Net working cap to sales %45.624.2 188.0%  
Current ratio x2.11.8 117.9%  
Inventory Days Days150100 149.6%  
Debtors Days Days11357 199.2%  
Net fixed assets Rs m5,14820,779 24.8%   
Share capital Rs m158252 62.7%   
"Free" reserves Rs m6,55624,499 26.8%   
Net worth Rs m6,73224,553 27.4%   
Long term debt Rs m9523,517 27.1%   
Total assets Rs m10,38839,595 26.2%  
Interest coverage x-45.812.2 -374.4%   
Debt to equity ratio x0.10.1 98.7%  
Sales to assets ratio x0.60.8 70.8%   
Return on assets %7.55.7 131.0%  
Return on equity %12.08.3 144.9%  
Return on capital %14.610.5 139.2%  
Exports to sales %74.548.6 153.1%   
Imports to sales %24.814.2 174.0%   
Exports (fob) Rs m4,44115,617 28.4%   
Imports (cif) Rs m1,4774,571 32.3%   
Fx inflow Rs m5,29815,617 33.9%   
Fx outflow Rs m1,7725,828 30.4%   
Net fx Rs m3,5259,790 36.0%   
CASH FLOW
From Operations Rs m1,2742,764 46.1%  
From Investments Rs m-1,204-1,432 84.1%  
From Financial Activity Rs m-196-1,591 12.3%  
Net Cashflow Rs m-126-259 48.8%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 9.6 25.3 37.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   42,599 36,892 115.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PANACEA BIOTECH  BIOCON LTD  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS